Description
Research indicates that peptides CJC-1295 and GHRP-6 may exhibit positive effects on growth hormones released in the body. When administered as a blend, they may induce a synergistic effect stimulating the body’s synthesis and secretion of growth hormones. This peptide blend may also help repair mild injuries associated with muscles and surrounding ligaments.
GHRP-6 peptide is a synthetic six amino acid peptide analog of ghrelin, a naturally occurring peptide that stimulates the secretion of growth hormones and helps maintain their concentrations in the body.(1)
CJC-1295 peptide is a synthetic 29 amino acid peptide analog of growth hormone-releasing hormone (GHRH), a naturally occurring hormone that stimulates the release of growth hormones in the body.(2)
CJC-1295 & GHRP-6 Chemical Makeup(2) (3)
Molecular Formula:
CJC-1295 peptide: C152H252N44O42
GHRP-6 peptide: C46H56N12O6
Molecular Weight:
CJC-1295 peptide: 3367.9 g/mol
GHRP-6 peptide: 873.0 g/mol
Other Known Titles:
“Growth hormone-releasing hexapeptide,” “CJC-1295 with DAC”, “CJC-1295 without DAC”. Both forms of the CJC-1295 peptide essentially exert the same effect; however, the addition of DAC (known as the drug affinity complex) appears to change the duration of the effect of the peptide. CJC-1295 with DAC may have a longer-lasting effect than CJC-1295 without DAC.
CJC-1295 & GHRP-6 Research
Studies in CJC-1295 & GHRP-6 and growth hormone levels
A clinical trial(4) was conducted in healthy male candidates aged between 20 and 40. All candidates were divided into two groups; one was administered with a placebo while the rest with the CJC-1295 peptide. A blood sample was collected from all the individuals before and after peptide administration. Based on these samples, researchers reported that administration of the peptide appeared to lead to a 7.5-fold increase in the subjects’ growth hormone levels compared to the placebo group. The growth hormone levels appeared to increase gradually and remained unchanged one week after the peptide administration.
In another study(5), the peptide was administered in ascending doses in a group of healthy volunteers aged between 20 and 60 years. All candidates were divided into two groups – one was administered with the peptide, while the other with a placebo. After the end of the study, when blood samples were examined, it was noted that there was a dose-dependent increment, up to 10-fold, in the levels of the subjects’ growth hormones. As per Madalina Ionescu, et al., “The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may benefit patients with intact pituitary GH secretory capability.”
In a study focusing on GHRP-6 peptide(6), children between 6 and 11 were administered the peptide. Some were only given the peptide, while the rest were administered with a blend of peptide and arginine (a growth hormone booster). After the completion of the study, it was reported that the growth hormone levels increased exponentially and in equal concentrations in all children, regardless of the presence of arginine.
CJC-1295 & GHRP-6 and hypothyroidism
Reduced growth hormone levels in the body characterize hypothyroidism. In a 1997 study(7), patients suffering from hypothyroidism were administered either with GHRP-6 peptide, GHRH peptide, or a blend of peptides (such as CJC-1295) and GHRP-6. Post-study, it was reported that patients subjected to the blend had significantly high levels of growth hormones than the individual peptides alone. The GHRP-6 peptide is an antagonist of somatostatin, an inhibitor of growth hormone secretion. Due to this, the peptide blend appears to yield a better result. As per F R Pimentel-Filho et al., “When GHRP-6 was associated with GHRH, a significant increase in the GH response was observed in these patients, which could suggest a role for somatostatin in this process. Our data suggest that thyroid hormones modulate GH release induced by GHRH and GHRP-6 through different mechanisms. However, additional studies are necessary to elucidate this hypothesis further.”
CJC-1295 and GHRP-6 peptide blend and cellular repair
Experimental animal models were induced with injury and multiple organ failure. They were then administered either the GHRP-6 peptide, or a combination of GHRP-6 and epidermal growth factor (EGF). Based on the laboratory results, it was observed that the peptide affected the gut epithelial cells of these animal subjects and appeared to increase cellular migration at three times the usual rate. In addition, it appeared to reduce any adverse effects of such failure by 50-85%.(8) These results suggest that when given in combination with CJC-1295, this peptide may have the added benefit of protecting the internal bodily system against failure.
CJC-1295 and GHRP-6 peptide blend and diabetes-induced gastrointestinal adversities
Diabetes significantly impacts the gastrointestinal system and reduces the gastric emptying rate and colonic and intestinal transit. Research(9) conducted on experimental mouse models induced with diabetes were subjected to growth hormone release-stimulating peptides (such as GHRP-6). The peptide administration appeared to increase the rate of gastric emptying and intestinal transit, suggesting the peptide’s effect in reversing the adversities caused by diabetes. No change was seen in the colonic transit. As per Zheng Q et al., peptides such as GHRP-6 “[have] therapeutic potential for diabetic patients with delayed upper gastrointestinal transit.”
CJC-1295 and GHRP-6 peptide blend and heart rate
Preliminary research(10) was conducted in mice that suggested GHRH derivative analogs (such as the CJC-1295 peptide) may have the potential to stabilize heart rate and improve functionality following a heart attack. Andrew V Schally et al. reported that the peptide appears to promote cardiac tissue repair and improve the blood pump capacity of the heart. The researchers observed that the results “[suggest] that GHRH agonists promote repair of cardiac tissue, improving ejection fraction and reducing infarct size in rats, reducing infarct scar in swine, and attenuating cardiac hypertrophy in mice, suggesting clinical applications.”
While the CJC-1295 and GHRP-6 peptide blend may potentially have positive effects, the peptide available in the market is for educational and research purposes only, and studies are ongoing.
References
- Berlanga-Acosta, Jorge, et al. “Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.” Clinical Medicine Insights. Cardiology vol. 11 1179546817694558. 2 Mar. 2017, doi:10.1177/1179546817694558. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392015/
- National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC.
- National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9919153, Growth hormone releasing hexapeptide. https://pubchem.ncbi.nlm.nih.gov/compound/Growth-hormone-releasing-hexapeptide.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Bellone J, Ghizzoni L, Amaretti G, Volta C, Boghen MF, Bernasconi S, Ghigo E. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995 Oct;133(4):425-9. https://pubmed.ncbi.nlm.nih.gov/7581965/
- Pimentel-Filho FR, Ramos-Dias JC, Ninno FB, Façanha CF, Liberman B, Lengyel AM. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism. Clin Endocrinol (Oxf). 1997 Mar;46(3):295-300. https://pubmed.ncbi.nlm.nih.gov/9156038/
- Cibrián D, Ajamieh H, Berlanga J, León OS, Alba JS, Kim MJ, Marchbank T, Boyle JJ, Freyre F, Garcia Del Barco D, Lopez-Saura P, Guillen G, Ghosh S, Goodlad RA, Playford RJ. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond). 2006 May;110(5):563-73. https://pubmed.ncbi.nlm.nih.gov/16417467/
- Zheng, Q., Qiu, W. C., Yan, J., Wang, W. G., Yu, S., Wang, Z. G., & Ai, K. X. (2008). Prokinetic effects of a ghrelin receptor agonist GHRP-6 in diabetic mice. World journal of gastroenterology, 14(30), 4795–4799. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739343/
NOTE: These products are intended for laboratory research use only. CJC-1295 & GHRP-6 blend for sale (10mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
